← Back to Search

Beta Agonist

Vascular Response Study in Obesity

Phase < 1
Recruiting
Led By Jacqueline Limberg, Ph.D.
Research Sponsored by University of Missouri-Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to last 1-minute of drug infusion
Awards & highlights

Study Summary

This trial looks at how sex and obesity affects blood vessels' ability to dilate in low-oxygen conditions.

Who is the study for?
This trial is for adults who are either at a healthy weight (BMI between 18 and 25) or obese (BMI of 30 or more). It's not suitable for those with nerve diseases, sleep apnea, major organ disease, high blood pressure, on prescription meds, sensitive to lidocaine, pregnant/breastfeeding women, smokers/nicotine users, or with bleeding/clotting disorders.Check my eligibility
What is being tested?
The study investigates how well blood vessels can widen in response to low oxygen levels in men vs. women and how obesity affects this process. Participants will receive drugs like Propranolol Hydrochloride and others that influence heart rate and blood vessel function.See study design
What are the potential side effects?
Possible side effects from the medications used might include changes in heart rate and blood pressure, dizziness or lightheadedness due to vasodilation effects. There may also be local reactions at the drug injection site.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to last 1-minute of drug infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to last 1-minute of drug infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in forearm vascular conductance with intra-arterial drug infusion

Trial Design

1Treatment groups
Experimental Treatment
Group I: Hypoxia ExposureExperimental Treatment4 Interventions
Men and women will be exposed to isocapnic hypoxia. Participants will wear a mask and systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Propranolol
FDA approved
Isoprenaline
FDA approved
Phentolamine Mesylate
2022
N/A
~20
Norepinephrine
FDA approved

Find a Location

Who is running the clinical trial?

University of Missouri-ColumbiaLead Sponsor
360 Previous Clinical Trials
627,892 Total Patients Enrolled
4 Trials studying Vasodilation
258 Patients Enrolled for Vasodilation
Jacqueline Limberg, Ph.D.Principal InvestigatorUniversity of Missouri-Columbia
1 Previous Clinical Trials
22 Total Patients Enrolled

Media Library

Isoproterenol (Beta Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05219799 — Phase < 1
Vasodilation Research Study Groups: Hypoxia Exposure
Vasodilation Clinical Trial 2023: Isoproterenol Highlights & Side Effects. Trial Name: NCT05219799 — Phase < 1
Isoproterenol (Beta Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05219799 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this medical trial allow for people under the age of 45 to participate?

"To be eligible for this trial, applicants must range between 18 and 45 years of age. Furthermore, there are 251 studies recruiting those under the legal limit of consent and 965 trials specifically targeting elderly populations."

Answered by AI

Could I potentially be a participant in this research?

"For this trial, 72 participants between 18 and 45 who suffer from vasodilation are being admitted. Criteria for admission include a healthy weight (BMI >18 and <25 kg/m2) or obesity (BMI ≥30 kg/m2)."

Answered by AI

Are new participants being enrolled in this trial at the present time?

"This research project, which was first posted on February 1st 2023 and updated last November 11th 2022, is not currently recruiting. Nonetheless, 1789 other trials are actively seeking out participants at present."

Answered by AI
~40 spots leftby Jul 2025